212 related articles for article (PubMed ID: 25227926)
21. The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.
Ros-Montañá J; Saoudi-Gonzalez N; Ortiz-Velez C; Muñoz-Couselo E
Melanoma Res; 2020 Apr; 30(2):209-212. PubMed ID: 31348136
[TBL] [Abstract][Full Text] [Related]
22. Advances and perspectives in immunotherapy of melanoma.
Schadendorf D; Vaubel J; Livingstone E; Zimmer L
Ann Oncol; 2012 Sep; 23 Suppl 10():x104-8. PubMed ID: 22987943
[TBL] [Abstract][Full Text] [Related]
23. Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab.
Uslu U; Agaimy A; Hundorfean G; Harrer T; Schuler G; Heinzerling L
J Immunother; 2015 Jun; 38(5):212-5. PubMed ID: 25962110
[TBL] [Abstract][Full Text] [Related]
24. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
Dick J; Enk A; Hassel JC
Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
[TBL] [Abstract][Full Text] [Related]
25. Treatment of metastatic melanoma: an overview.
Bhatia S; Tykodi SS; Thompson JA
Oncology (Williston Park); 2009 May; 23(6):488-96. PubMed ID: 19544689
[TBL] [Abstract][Full Text] [Related]
26. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.
Bossart S; Thurneysen S; Rushing E; Frontzek K; Leske H; Mihic-Probst D; Nagel HW; Mangana J; Goldinger SM; Dummer R
Oncologist; 2017 Jun; 22(6):749-753. PubMed ID: 28559410
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy of melanoma: present options and future promises.
Rotte A; Bhandaru M; Zhou Y; McElwee KJ
Cancer Metastasis Rev; 2015 Mar; 34(1):115-28. PubMed ID: 25589384
[TBL] [Abstract][Full Text] [Related]
29. Advances in immunotherapy for melanoma.
Redman JM; Gibney GT; Atkins MB
BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
[TBL] [Abstract][Full Text] [Related]
30. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
32. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
Cheng F; Loscalzo J
Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
[TBL] [Abstract][Full Text] [Related]
33. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Saenger YM; Wolchok JD
Cancer Immun; 2008 Jan; 8():1. PubMed ID: 18198818
[TBL] [Abstract][Full Text] [Related]
34. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
[TBL] [Abstract][Full Text] [Related]
35. High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.
Bastholt L; Svane IM; Bjerregaard JK; Herrstedt J; Hróbjartsson A; Schmidt H
Eur J Cancer; 2019 Jul; 115():61-67. PubMed ID: 31108244
[TBL] [Abstract][Full Text] [Related]
36. Current systemic therapies for melanoma.
Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Buchbinder EI; McDermott DF
Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
[TBL] [Abstract][Full Text] [Related]
38. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A; Eichner F; Amaral T; Keim U; Garbe C; Eigentler TK
J Cancer Res Clin Oncol; 2017 Mar; 143(3):533-540. PubMed ID: 27878363
[TBL] [Abstract][Full Text] [Related]
39. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
40. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
